文献速递皮肤肿瘤

单病灶皮肤癌风险分层分诊路径

Single-Lesion Skin Cancer Risk Stratification Triage Pathway.
PubMed 文献 · JAMA Dermatol · 2024-01-01

结果显示经病灶路径就诊者恶性活检风险更高(aRR 1.6,95%CI 1.4-1.9),黑色素瘤风险更高(aRR 2.0,95%CI 1.2-3.2),三个高危病灶组就诊更快(平均缩短26天,95%CI 18-34天)。

要点

  • 基于规则的分诊路径可优先安排高危皮肤病灶患者,缩短转诊至初诊时间。
  • 经病灶路径就诊者恶性活检和黑色素瘤风险显著高于非路径患者。
  • 转诊医生怀疑皮肤癌的病灶与皮肤癌风险升高相关,支持风险分层分诊。

核心结论

  • 基于规则的自动转诊路径可加快高危皮肤癌患者的诊疗,可能改善患者分层并缩短转诊至初诊时间,同时维持恶性病灶识别准确性。

研究设计与样本

  • 暴露因素为初级保健医生提供的转诊原因和风险因素;主要结局为就诊时或就诊后6个月内活检诊断的任何皮肤癌和黑色素瘤。

主要发现

  • 经病灶路径就诊者恶性活检风险更高(aRR 1.6,95%CI 1.4-1.9),黑色素瘤风险更高(aRR 2.0,95%CI 1.2-3.2)。
  • 转诊医生怀疑皮肤癌的病灶与皮肤癌风险升高相关(所有皮肤癌:aRR 2.8,95%CI 2.2-3.5;黑色素瘤:aRR 2.02,95%CI 1.1-3.7)。
  • 三个高危病灶组患者在新分诊路径中就诊更快(平均缩短26天,95%CI 18-34天)。

临床怎么用

  • 可依据高危病灶特征(如转诊医生怀疑皮肤癌)建立基于规则的转诊分诊路径,优先安排高危患者就诊。
  • 该路径有助于优化临床资源分配,缩短高危皮肤癌患者的转诊至初诊时间。

局限性

  • 本研究为单中心回顾性质量改进队列研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Access to timely dermatologic care remains a challenge, especially for patients with new skin lesions. Assessing the efficiency of new triage pathways may assist in better resource allocation and shorter time to care. OBJECTIVE: To evaluate whether a rule-based triage system was associated with better skin cancer risk stratification of patients and reduced wait times. DESIGN, SETTING, AND PARTICIPANTS: This retrospective quality improvement cohort study of patients referred to Stanford University dermatology clinics was conducted between November 2017 and January 2023. A rules-based triage system based on a priori-determined high-risk lesion characteristics was implemented. EXPOSURES: Referral reasons and risk factors of patients provided by their primary care physicians. MAIN OUTCOMES AND MEASURES: Biopsy results of patients (diagnosis of any skin cancer and melanoma) at their visit or within 6 months after the visit. Regression models were used to assess the association between risk factors at referral and (1) biopsy outcomes and (2) time to first visit, adjusting for sociodemographic factors. RESULTS: Among 37 478 patients (mean [SD] age, 54 (18) years; 21 292 women [57%]), the rates of aggregate biopsy, malignant biopsy specimens, and melanoma were comparable across patients seen after (n = 12 302) and before (n = 25 176) the implementation of the new triage pathway. Patients seen through the lesion pathway had a higher risk of having malignant biopsy results (adjusted risk ratio [aRR], 1.6; 95% CI, 1.4-1.9) and melanoma (aRR, 2.0; 95% CI, 1.2-3.2) than those not seen through the pathway. Lesions that were concerning to referring clinicians for skin cancer were associated with an increased risk of skin cancer (all skin cancer: aRR, 2.8; 95% CI, 2.2-3.5; melanoma: aRR, 2.02; 95% CI, 1.1-3.7). Patients in the 3 high-risk lesion groups were seen faster in the new triage pathway (mean reduction, 26 days; 95% CI, 18-34 days). CONCLUSIONS AND RELEVANCE: In this study, a new automated, rules-based referral pathway was implemented that expedited care for patients with high-risk skin cancer. This reform may have contributed to improving patient stratification, reducing the time from referral to first encounter, and maintaining accuracy in identifying malignant lesions. The findings highlight the potential to optimize clinical resource allocation by better risk stratification of referred patients.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Gui H, Yao H, et al. Single-Lesion Skin Cancer Risk Stratification Triage Pathway. JAMA Dermatol. 2024. PMID: 38922597. doi:10.1001/jamadermatol.2024.1832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。